MGNX Stock — MacroGenics Inc.: Cash, EV, Pipeline

Share price

$4.14

Market cap

$263.7M

Cash

$113.9M

Enterprise value

$149.8M

Balance sheet

Cash	$113.9M
Debt	$0.0M
Net cash	$113.9M
Enterprise value	$149.8M
Basic shares	63.6M shares
Fully diluted shares	78.5M shares
Fully diluted market cap	$324.8M
Cash per share	$1.79

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MGNX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027	MGD024	Phase 1	Leukemia, Acute Myeloid; Myelodysplastic Syndromes; Classical Hodgkin Lymphoma	—
Dec 13, 2026 - Jan 24, 2027	MGC028	Phase 1	Advanced Solid Tumors; NSCLC Adenocarcinoma; Cholangiocarcinoma	—
Aug 12 - Sep 23	Lorigerlimab	Phase 2	Platinum-resistant Ovarian Cancer; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma	—
Jun 12 - Jul 24	MGC026 Dose Escalation	Phase 1	Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer	—
Oct 13 - Nov 24	MGC030	Phase 1	Urothelial Cancer; GastroEsophageal Cancer; Colorectal Cancer	—
Jul 13 - Aug 24	Lorigerlimab	Phase 2	Pancreatic Adenocarcinoma; Homologous Recombination Deficiency	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

MGC026

Phase 1 · Active Modality: antibody-drug conjugate (ADC)

Target B7-H3

Indications

solid tumors (Phase 1)

Status note ADC incorporating a B7-H3-targeting antibody with the SYNtecan E novel TOP1i-based linker-payload (exatecan-based, cleavable). Phase 1 dose escalation initiated 2024; enrollment completed 2025.

MGC028

Phase 1 · Active Modality: antibody-drug conjugate (ADC)

Target ADAM9

Indications

advanced solid tumors (Phase 1)

Catalysts

— second half of 2026

Status note First-in-class ADC with novel TOP1i-based linker-payload; Phase 1 dose escalation ongoing.

MGC030

Preclinical · Active Modality: antibody-drug conjugate (ADC)

Target undisclosed antigen

Indications

solid tumors (Preclinical)

Catalysts

— third quarter of 2026

Status note First-in-class ADC with novel TOP1i-based linker-payload against an undisclosed antigen expressed across several solid tumors; IND targeted for Q3 2026. Additional preclinical ADC and next-generation T-cell engager programs undescribed as distinct candidates.

Lorigerlimab

Phase 2 · Active Modality: bispecific DART molecule

Target PD-1 x CTLA-4

Indications

platinum-resistant ovarian cancer (LINNET study) (Phase 2)
clear cell gynecologic cancer (LINNET study) (Phase 2)

Catalysts

— mid-2026

Status note PD-1 x CTLA-4 bispecific DART. LINNET study (PROC, Simon two-stage): FDA partial clinical hold initiated February 2026 after enrollment pause for safety events; current participants may continue. LORIKEET (2L mCRPC vs docetaxel): development discontinued (November 2025) after LORIKEET interim data did not support further development; candidate status stays ACTIVE (LINNET continues) per brief.

MGD024

Phase 1 · Active Modality: bispecific DART molecule (next-generation T-cell engager)

Target CD123 x CD3

Partnerships Gilead: exclusive option and collaboration agreement (October 2022) to develop and commercialize MGD024 plus up to two separate bispecific research programs; Gilead nominated the second research program in November 2025

Indications

CD123-positive neoplasms (incl. AML and MDS) (Phase 1)

Status note Phase 1 dose escalation ongoing in CD123-positive neoplasms including AML and MDS.

Vobramitamab duocarmazine

Phase 2 · Terminated Modality: antibody-drug conjugate (ADC)

Aliases vobra duo

Target B7-H3

Partnerships Byondis: ADC technology license

Indications

metastatic castration-resistant prostate cancer (TAMARACK study) (Phase 2)

Status note B7-H3 ADC with DNA-alkylating duocarmycin payload. TAMARACK study treatment discontinued for remaining mCRPC participants in July 2024 on safety recommendation; March 2025 company announced results did not support future investment and discontinued MacroGenics-based development.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Lorigerlimab
Lead indication	Platinum-resistant Ovarian Cancer
Lead phase	Phase 2
Active trials	5
Collaborator trials	7

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06730347	Phase 2	Recruiting	Sponsor	MacroGenics	—	Platinum-resistant Ovarian Cancer; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma	—
NCT05362773	Phase 1	Active, not recruiting	Sponsor	MacroGenics	—	Leukemia, Acute Myeloid; Myelodysplastic Syndromes; Classical Hodgkin Lymphoma	—
NCT06723236	Phase 1	Recruiting	Sponsor	MacroGenics	—	Advanced Solid Tumors; NSCLC Adenocarcinoma; Cholangiocarcinoma	—
NCT06242470	Phase 1	Recruiting	Sponsor	MacroGenics	—	Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer	—
NCT07822399	Phase 1	Not yet recruiting	Sponsor	MacroGenics	—	Urothelial Cancer; GastroEsophageal Cancer; Colorectal Cancer	—
NCT07071961	Phase 2	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Colorectal Cancer; Regorafenib; High Risk Patients	—
NCT05475171	Phase 2	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Metastatic Cancer; Cervical Cancer	—
NCT06014255	Phase 2	Active, not recruiting	Collaborator	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	—	Prostate Cancer	—
NCT07565155	Phase 2	Not yet recruiting	Collaborator	Peter Hosein, MD	—	Pancreatic Adenocarcinoma; Homologous Recombination Deficiency	—
NCT02923180	Phase 2	Active, not recruiting	Collaborator	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	—	Prostate Cancer	—
NCT04425018	Phase 2	Active, not recruiting	Collaborator	Dana-Farber Cancer Institute	—	Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer	—
NCT06227546	Phase 2	Active, not recruiting	Collaborator	Georgetown University	—	Extensive-stage Small-cell Lung Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 7 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 12 active trials for MacroGenics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	129,822	+89,822	0.03%	2026-08-14
Ikarian Capital	74,893	no change	0.06%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

MGNX — MacroGenics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders